Description: Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities in Canada and internationally. Its natural psilocybin is used for the long-term treatment of psychological trauma and its mental health consequences. The company also engages in developing therapeutic, hallucinogenic and subhallucinogenic dosing, and treatment protocols for the treatment of anxiety, depression, PTSD, grief, and bereavement. In addition, it focuses on the development of over-the-counter IP protected nutraceutical products for mental wellbeing. The company has a collaboration agreement with Scientific Research Council of Jamaica for psilocybin product development. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
Home Page: psyence.com
121 Richmond Street West
Toronto,
ON
M5H 2K1
Canada
Phone:
416-477-1708
Officers
| Name | Title |
|---|---|
| Mr. Jody Aufrichtig | Co-Founder & Executive Chairman |
| Ms. Adri Botha | Interim Chief Financial Officer |
| Ms. Taryn Vos | General Counsel |
| Mr. Tony Budden | Chief Strategy Officer |
| Ms. Mary-Elizabeth Gifford | Executive Vice President for Public Policy & Global Impact |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.2874 |
| Price-to-Sales TTM: | 1358.7928 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |